MedTrace Logo

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

NCT00914303 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 77

Last updated 2010-04-06

No results posted yet for this study

Summary

The aims of the study are to assess the safety, tolerability and pharmacokinetics of ER tablets of AZD3241 following multiple ascending doses administered to healthy male and female subjects including the effect of food.

Conditions

  • Healthy

Interventions

DRUG

AZD3241

Oral Tablet, Repeated Administration

DRUG

Placebo Tablet

Oral Tablet. Repeated Administration

Sponsors & Collaborators

Principal Investigators

  • Rolf Karlsten, MD · Medical Science Director AstraZeneca R&D Södertälje.

  • Wolfgang Kuhn, MD, PhD · Quintiles AB Phase I Unit, Uppsala, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-03-31
Completion
2010-03-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00914303 on ClinicalTrials.gov